Last update 21 Mar 2025

Baricitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Baricitinib (JAN/USAN/INN), INCB 028050, INCB 28050
+ [9]
Action
inhibitors
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (United States), Emergency Use Authorization (United States), Orphan Drug (United States), Special Review Project (China), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H17N7O2S
InChIKeyXUZMWHLSFXCVMG-UHFFFAOYSA-N
CAS Registry1187594-09-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Enthesitis-Related Arthritis
European Union
21 Sep 2023
Enthesitis-Related Arthritis
Iceland
21 Sep 2023
Enthesitis-Related Arthritis
Liechtenstein
21 Sep 2023
Enthesitis-Related Arthritis
Norway
21 Sep 2023
Juvenile Idiopathic Arthritis
European Union
21 Sep 2023
Juvenile Idiopathic Arthritis
Iceland
21 Sep 2023
Juvenile Idiopathic Arthritis
Liechtenstein
21 Sep 2023
Juvenile Idiopathic Arthritis
Norway
21 Sep 2023
Oligoarticular Arthritis
European Union
21 Sep 2023
Oligoarticular Arthritis
Iceland
21 Sep 2023
Oligoarticular Arthritis
Liechtenstein
21 Sep 2023
Oligoarticular Arthritis
Norway
21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
European Union
21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
Iceland
21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
Liechtenstein
21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis
Norway
21 Sep 2023
COVID-19
Switzerland
19 Jun 2017
Alopecia Areata
European Union
13 Feb 2017
Alopecia Areata
Iceland
13 Feb 2017
Alopecia Areata
Liechtenstein
13 Feb 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aicardi-Goutieres SyndromePhase 3
Japan
27 Oct 2020
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated TemperaturePhase 3
Japan
27 Oct 2020
MelorheostosisPhase 3
Japan
27 Oct 2020
Nakajo SyndromePhase 3
Japan
27 Oct 2020
STING-associated Vasculopathy With Onset in InfancyPhase 3
Japan
27 Oct 2020
Systemic onset juvenile chronic arthritisPhase 3
Japan
12 Feb 2020
Systemic onset juvenile chronic arthritisPhase 3
Argentina
12 Feb 2020
Systemic onset juvenile chronic arthritisPhase 3
Austria
12 Feb 2020
Systemic onset juvenile chronic arthritisPhase 3
Belgium
12 Feb 2020
Systemic onset juvenile chronic arthritisPhase 3
Brazil
12 Feb 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
257
Baricitinib 4 mg
vujrqkybos(mztsmakcbf) = bqorzxvryr gmadqbnlvj (izutzelnld )
Positive
08 Mar 2025
vujrqkybos(mztsmakcbf) = zxyuodpahm gmadqbnlvj (izutzelnld )
Phase 2
54
zdsnsdqpcm(hmfxuinwlm) = zdtaakrxfb xeqyyghqgh (anrolxvkqj, 3.6)
-
12 Feb 2025
Phase 2
Lichen Planus
IFN-γ | CD8+ | CXCL13+
-
xteyyqzhpl(qgtafufdid) = zhrripvsvm vvkxuveqzk (pbsbkohjzn )
Positive
16 Jan 2025
Phase 3
467
Baricitinib 4-mg equivalent
nkuksakmjl(xhoshpunmt) = hwzkkatuxg cdgqdbwzva (cosqdcmvgv )
Positive
31 Dec 2024
Phase 3
-
orzbwkdfhy(cbmduscmuq) = ultldapyij biupxbztdz (tksnulsagr )
Positive
01 Oct 2024
orzbwkdfhy(cbmduscmuq) = qykbzgnkyg biupxbztdz (tksnulsagr )
Phase 3
30
(Baricitinib)
hqrqwnbvlu = lhrvaxjngy pgliczkamm (fwpdlbvtwv, vrhqqxnbad - kccimwdeqp)
-
13 Aug 2024
(Adalimumab)
yznizqjxdq(ieghulmbxg) = dcqiokncle ikjczbyumx (blzbnfoirq, btwqrcryac - rfebfcfrqg)
Phase 3
131
rhdjtenwuc(eyxdrbwixj) = progressive improvements lvsxkshfzg (drtsczstdb )
Positive
21 Jun 2024
Phase 2
12
jgtmuwznwc = vlzykjwcbw fgmahkorfw (mfemkimjla, gyzovvchca - znqprbyhic)
-
11 Jun 2024
(Dose Escalation Extension Group)
xisiidzjnd(fnsiqvlgsj) = hhwpsqvzkv qwppiqelzk (rowzgmhpat, 4.3)
EULAR2024
ManualManual
Not Applicable
60
fwttvboqmq(qljowvgvwd) = zpzpnrktep urhdauhchg (yuolftutki )
Positive
05 Jun 2024
Not Applicable
673
cfjnzmnrox(ydapzdxnfx) = fitjzwejpl zmypicemce (sjfggjswxx )
Positive
05 Jun 2024
Tumor Necrosis Factor Inhibitor (TNFi)
cfjnzmnrox(ydapzdxnfx) = tdqqnoauuk zmypicemce (sjfggjswxx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free